Autolus Therapeutics (NASDAQ:AUTL) Reaches New 1-Year Low – What’s Next?

Autolus Therapeutics plc (NASDAQ:AUTL) shares reached a new 52-week low on Thursday . The company traded as low as $2.29 and last traded at $2.29, with a volume of 2277337 shares trading hands. The stock had previously closed at $2.49.

Analyst Ratings Changes

A number of equities analysts recently issued reports on AUTL shares. Needham & Company LLC reissued a “buy” rating and issued a $10.00 price objective on shares of Autolus Therapeutics in a report on Thursday, December 5th. The Goldman Sachs Group raised Autolus Therapeutics from a “neutral” rating to a “buy” rating and raised their price target for the company from $7.00 to $7.60 in a report on Monday, November 18th. Finally, Redburn Atlantic raised shares of Autolus Therapeutics from a “neutral” rating to a “buy” rating and set a $13.00 price objective for the company in a report on Friday, November 15th. Five analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Autolus Therapeutics currently has an average rating of “Buy” and an average price target of $10.40.

Autolus Therapeutics Stock Performance

The company has a market cap of $609.36 million, a P/E ratio of -1.89 and a beta of 1.98. The stock has a 50 day moving average price of $3.45 and a 200 day moving average price of $3.80.

Autolus Therapeutics (NASDAQ:AUTL) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($0.31) EPS for the quarter, missing the consensus estimate of ($0.21) by ($0.10). During the same period in the previous year, the company posted ($0.26) EPS. As a group, equities research analysts predict that Autolus Therapeutics plc will post -0.94 earnings per share for the current year.

Institutional Trading of Autolus Therapeutics

A number of large investors have recently added to or reduced their stakes in AUTL. ProShare Advisors LLC bought a new position in shares of Autolus Therapeutics in the second quarter valued at $43,000. Capstone Investment Advisors LLC purchased a new stake in shares of Autolus Therapeutics during the third quarter valued at $51,000. Daiwa Securities Group Inc. boosted its position in shares of Autolus Therapeutics by 2,659.7% in the 2nd quarter. Daiwa Securities Group Inc. now owns 15,868 shares of the company’s stock valued at $55,000 after purchasing an additional 15,293 shares during the period. Herbst Group LLC purchased a new position in Autolus Therapeutics in the 3rd quarter worth about $91,000. Finally, China Universal Asset Management Co. Ltd. raised its holdings in Autolus Therapeutics by 63.8% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 38,393 shares of the company’s stock worth $139,000 after buying an additional 14,959 shares during the period. 72.83% of the stock is currently owned by institutional investors.

Autolus Therapeutics Company Profile

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.